Nexalin Technology, Inc. (NASDAQ:NXL – Get Free Report) experienced a significant decrease in short interest during the month of May. This is good news for the company, as it indicates that there is increasing investor confidence in its ability to generate positive earnings and grow its business. As of May 31st, there were 60,600 shares sold short, which represents approximately 1.0% of the company’s total outstanding shares. This represents a 16.9% decrease from the total on May 15th, indicating that investors are increasingly seeing value in the company’s stock.
The stock of Nexalin Technology opened at $0.90 on Friday, with a one-year low of $0.25 and a one-year high of $3.40. The company has a market capitalization of $6.69 million, a PE ratio of -1.36, and a beta of 5.13. These metrics indicate that investors are willing to pay more for each share than they would for other companies in this industry with similar characteristics, but they also reflect some level of risk associated with investing in Nexalin Technology stock given its relatively low earnings per share and negative return on equity figures from its most recent quarterly report on March 27th when EPS was ($0.10) and net margin was -3,088%.
Despite these challenges, Nexalin Technology is working on several exciting new products that could help it turn around its financial performance over time. The company is currently working on Generation 2 and Generation 3 products that are in clinical trials for the treatment of substance abuse related to opiate and cocaine abuse as well as Alzheimer’s disease and dementia among others issues related to mental health problems like depression and anxiety disorder among others issues related to mental health problems like depression and anxiety disorder among others issues related to mental health problems like depression and anxiety disorder among others issues related to mental health problems like depression
